|Videos|April 12, 2023
Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for early-stage cutaneous melanoma.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
The resubmission of the BLA for RP1 has been accepted for review by the FDA for use in combination with nivolumab in advanced melanoma.
Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving biomarker utilization and sequencing strategies in uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
2
FDA Issues CRL to Orviglance for Liver Metastasis Imaging in Patients With Severe Kidney Impairment
3
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
4
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
5